JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will ...

JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, announced today that it entered into a securit ...

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland B ...

JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (NASDAQ:MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins ("HCP") from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Under the terms of the partnership agreement, Cygnus has developed the C1 HCP E ...

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be fun ...

JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the followin ...

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode. Following ...

Financial Performance - Total revenue for Q3 2023 was $397,060, a decrease of 55.1% compared to $879,597 in Q3 2022[15] - Net loss for Q3 2023 was $1,614,259, compared to a net loss of $1,809,173 in Q3 2022, representing a 10.8% improvement[15] - Total costs and expenses for the nine months ended September 30, 2023, were $8,273,313, down 18.2% from $10,112,687 in the same period of 2022[15] - The Company reported other income of approximately $1,018,000 for the nine months ended September 30, 2023, compared to $250,000 in the same period of 2022[65] - The net loss for the three months ended September 30, 2023, was approximately $1,614,000, a decrease from $1,809,000 for the same period in 2022. For the nine months ended September 30, 2023, the net loss was approximately $4,724,000 compared to $7,589,000 in 2022[166] Cash and Liquidity - Cash and cash equivalents increased to $7,403,176 as of September 30, 2023, from $5,794,272 at the beginning of the period[20] - The company anticipates that its existing cash and cash equivalents will be sufficient to meet operational requirements for at least the next twelve months[25] - The company expects to incur losses and negative net cash flows from operating activities as it continues to develop its microbial platforms and related products[24] - Net cash used in operating activities for the nine months ended September 30, 2023, was approximately $5.8 million, primarily due to a net loss of approximately $4.7 million[174] - Net cash provided by investing activities for the nine months ended September 30, 2023, was approximately $7.4 million, compared to a net cash used of $3.0 million for the same period in 2022[176] Research and Development - Research and development revenue for the nine months ended September 30, 2023, increased to $2,079,918, up 4.8% from $1,983,636 in the same period of 2022[15] - Research and development costs for the three months ended September 30, 2023, were $716,351, a slight decrease of 3.7% from $743,585 in the same period of 2022[59] - For the nine months ended September 30, 2023, total research and development costs were $2,444,469, down 37.5% from $3,917,245 in 2022[59] - Research and development revenue for the three months ended September 30, 2023, was $352,942, a decrease from $835,480 in the same period of 2022[157] - The decrease in research and development revenue for the three months ended September 30, 2023, was attributed to several research projects winding down or on hold due to a laboratory relocation[157] Assets and Liabilities - Total current liabilities decreased by 40.5% to $1,457,357 as of September 30, 2023, down from $2,448,608 at the end of 2022[13] - Stockholders' equity decreased to $7,652,524 as of September 30, 2023, from $11,087,739 at the end of 2022, a decline of 30.5%[13] - As of September 30, 2023, accounts receivable totaled $417,878, an increase from $330,001 as of December 31, 2022[49] - As of September 30, 2023, accounts payable totaled $600,148, a decrease from $1,276,313 as of December 31, 2022[51] - As of September 30, 2023, accrued expenses totaled $620,242, a decrease of 34.9% from $955,081 as of December 31, 2022[52] Collaborations and Agreements - The company is involved in multiple funded research collaborations with pharmaceutical companies to leverage its C1-cell protein production platform[22] - The Company signed a Development and Exclusive License Agreement with Inzymes ApS on September 18, 2023, which includes an upfront payment of $0.6 million for research collaboration[77][78] - The Global Food Ingredient Company (GFIC) completed its one-year funding commitment of approximately $1.35 million for the initial phase of research collaboration as of September 30, 2023[82] - The Janssen collaboration is set to wind down with an effective end date of December 31, 2023, as notified by Janssen on October 2, 2023[88] - The company entered into a development and commercialization agreement with bYoRNA on September 26, 2023, to combine RNA platforms for more cost-efficient mRNA production[129] Other Income and Expenses - Interest income for Q3 2023 was $105,862, an increase of 95.3% compared to $54,300 in Q3 2022[15] - General and administrative expenses for the three months ended September 30, 2023, decreased by 7.3% to approximately $1,282,000 compared to $1,383,000 for the same period a year ago[161] - General and administrative expenses for the nine months ended September 30, 2023, decreased by 12.4% to approximately $4,165,000 compared to $4,753,000 for the same period a year ago[162] - Interest income for the nine months ended September 30, 2023, was approximately $320,000, an increase from $87,000 in the same period a year ago[164] - The company recognized total non-cash share-based compensation expense of $946,262 for the nine months ended September 30, 2023, compared to $1,408,210 for the same period in 2022[116]

Dyadic International, Inc. (NASDAQ:DYAI) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) | | | Large accelerated filer ...